Using the more stringent PD-L1 IHC scoring cutoff (TPS ≥ 50), 29.3% (311/1063) of the patients with NSCLC-BM were positive PD-L1 IHC, and 17.6% (187/1063) of patients were positive for PD-L1 IHC and TMB-High (Fig. 3B). The gene discussed is CD274; the disease is non-small cell lung carcinoma.